* women who are pregnant or breastfeeding. * enrolling in or planning to participate other interventional clinical study. * has received systemic immunoglobulins or blood products within 3 months prior to the day of screening. * history of anaphylaxis, urticaria, or other significant adverse reaction requiring medical intervention after receipt of a vaccine. * bleeding disorder considered a contraindication to intramuscular injection or phlebotomy. * continued using anticoagulants such as coumarin and related anticoagulants (i.e., warfarin) or oral anticoagulants (i.e., apixaban, rivaroxaban, dabigatran, and edoxaban). * having coronary heart disease, hypertension, diabetes, chronic respiratory diseases, tumors and poorly controlled. * immunocompromised or having immunosuppressive therapy. * suspected or confirmed alcohol/drug dependence. * investigator decide unsuitable factors for participating in clinical trials in the investigator's judgment

* women who are pregnant or breastfeeding. * enrolling in or planning to participate other interventional clinical study. * has received systemic immunoglobulins or blood products within 3 months prior to the day of screening. * history of anaphylaxis, urticaria, or other significant adverse reaction requiring medical intervention after receipt of a vaccine. * bleeding disorder considered a contraindication to intramuscular injection or phlebotomy. * continued using anticoagulants such as coumarin and related anticoagulants (i.e., warfarin) or oral anticoagulants (i.e., apixaban, rivaroxaban, dabigatran, and edoxaban). * having coronary heart disease, hypertension, diabetes, chronic respiratory diseases, tumors and poorly controlled. * immunocompromised or having immunosuppressive therapy. * suspected or confirmed alcohol/drug dependence. * investigator decide unsuitable factors for participating in clinical trials in the investigator's judgment

women who are pregnant or breastfeeding. enrolling in or planning to participate other interventional clinical study. has received systemic immunoglobulins or blood products within 3 months prior to the day of screening. history of anaphylaxis, urticaria, or other significant adverse reaction requiring medical intervention after receipt of a vaccine. bleeding disorder considered a contraindication to intramuscular injection or phlebotomy. continued using anticoagulants such as coumarin and related anticoagulants (i.e., warfarin) or oral anticoagulants (i.e., apixaban, rivaroxaban, dabigatran, and edoxaban). having coronary heart disease, hypertension, diabetes, chronic respiratory diseases, tumors and poorly controlled. immunocompromised or having immunosuppressive therapy. suspected or confirmed alcohol/drug dependence. investigator decide unsuitable factors for participating in clinical trials in the investigator's judgment

women who are pregnant or breastfeeding. enrolling in or planning to participate other interventional clinical study. has received systemic immunoglobulins or blood products within 3 months prior to the day of screening. history of anaphylaxis, urticaria, or other significant adverse reaction requiring medical intervention after receipt of a vaccine. bleeding disorder considered a contraindication to intramuscular injection or phlebotomy. continued using anticoagulants such as coumarin and related anticoagulants (i.e., warfarin) or oral anticoagulants (i.e., apixaban, rivaroxaban, dabigatran, and edoxaban). having coronary heart disease, hypertension, diabetes, chronic respiratory diseases, tumors and poorly controlled. immunocompromised or having immunosuppressive therapy. suspected or confirmed alcohol/drug dependence. investigator decide unsuitable factors for participating in clinical trials in the investigator's judgment